Skip to main content
OpenTrials

Clinical trial condition

Relapsed and/or Refractory Multiple Myeloma

Explore clinical trials studying Relapsed and/or Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

11 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Relapsed and/or Refractory Multiple Myeloma trial results

Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCSF Helen Diller Medical Center at Parnassus Heights San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
View all 19 locations
View Trial Details
Recruiting

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

NCT06182696

Conditions
Relapsed and/or Refractory Multiple Myeloma
Locations
  • The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou, Zhejiang, China
  • Beijing GoBroad Hospital Beijing, China
  • The First Affiliated Hospital with Nanjing Medical University Nanjing, China
  • Tongji Hospital of Tongji University Shanghai, China
View Trial Details
Completed

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

NCT03170882

Conditions
Relapsed and/or Refractory Multiple Myeloma
Locations
  • Highlands Oncology Group Fayetteville, Arkansas, United States
  • St Joseph Heritage Healthcare Santa Rosa, California, United States
  • Lynn Cancer Institute Boca Raton, Florida, United States
  • University of Florida Gainesville, Florida, United States
View all 111 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

NCT03416374

Conditions
Relapsed and/or Refractory Multiple Myeloma
Locations
  • Kameda Medical Center Kamogawa, Chiba, Japan
  • The Jikei University Kashiwa Hospital Kashiwa, Chiba, Japan
  • Ogaki Municipal Hospital Ōgaki, Gifu, Japan
  • Gunma University Hospital Maebashi, Gunma, Japan
View all 23 locations
View Trial Details
Completed

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

NCT02831686

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memoral Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

NCT00882063

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Jaslok Hospital & Research Centre Mumbai, Maharashtra, India
  • Shatabdi Superspeciality Hospital Nashik, Maharashtra, India
  • Rajiv Gandhi Cancer Institute And Research Centre Delhi, National Capital Territory of Delhi, India
  • Institute Rotary Cancer Hospital,All India Institute Of Medical Sciences(AIIMS) New Delhi, India
View Trial Details

Related conditions